Loading...
₹ 0
0.00%
Loading...
About
Loading... [1]
- Market Cap ₹ 0 Cr.
- Current Price ₹ 0
- High / Low ₹ 0 / 0
- Stock P/E
- Dividend Yield 0 %
- ROE 0 %
- EPS 0
- P/B Ratio 0
- Net Profit Margin 0 %
- Debt to Equity 0
- ROCE 0 %
- Interest Coverage 0 %
Stock News - Refractory
Latest updates related to Refractory
| Sr No. | Title | Sentiment |
|---|---|---|
| 1 | Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma PR Newswire | 🔄 |
| 2 | Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting PR Newswire | 🔄 |
| 3 | Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) PR Newswire | 🔄 |
| 4 | Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study ASCO Journals | 🔄 |
| 5 | Refractory Shapes (NSE:REFRACTORY) Has A Pretty Healthy Balance Sheet Simply Wall St | 🔄 |
| 6 | Trevi soars on hopes for refractory chronic cough treatment FirstWord Pharma | 🔄 |
| 7 | Plansee SE acquires Hammer Evo35 from Incus to advance refractory metal 3D printing VoxelMatters | 🔄 |
| 8 | FDA Approves New Combined Therapy for Relapsed or Refractory DLBCL Oncology Nurse Advisor | 🔄 |
| 9 | Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough PR Newswire | 🔄 |
| 10 | Botulinum toxin is helpful in refractory NE Contemporary Pediatrics | 🔄 |
Loading peers table...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Loading data...
Quarterly Data Visualization
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Loading Profit & Loss data...
Profit & Loss Data Visualization:
| Compounded Sales Growth | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| TTM: | |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| TTM: | |
| Stock Price CAGR | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| 1 Year: | |
| Return on Equity | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| Last Year: | |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Balance Sheet Data Visualization:
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Ratios
Consolidated Figures in Rs. Crores / View Standalone